SNYNF:OTO-Sanofi (USD)

COMMON STOCK | Drug Manufacturers—General | OTC Pink

Last Closing

USD 94.4

Change

-2.35 (-2.43)%

Market Cap

USD 112.02B

Volume

2.00K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Sanofi SA is a healthcare company engaged in the research, development, manufacture and marketing of healthcare products.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-04-08 )

Largest Industry Peers for Drug Manufacturers—General

ETFs Containing SNYNF

SEUC:PA SSgA SPDR ETFs Europe I p.. 0.32 % 0.00 %

N/A

USD 1.26B
SYBD:F SSgA SPDR ETFs Europe I p.. 0.32 % 0.00 %

-0.01 (-0.01%)

USD 1.26B
SYBD:XETRA SPDR® Bloomberg 0-3 Year.. 0.32 % 0.00 %

N/A

USD 1.27B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers—General) Market Performance vs. Exchange (OTC Pink)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -5.17% 71% C- 73% C
Dividend Return N/A N/A N/A N/A N/A
Total Return -5.17% 71% C- 73% C
Trailing 12 Months  
Capital Gain 8.63% 69% C- 80% B-
Dividend Return 3.53% 77% C+ 64% D
Total Return 12.16% 63% D 80% B-
Trailing 5 Years  
Capital Gain -9.04% 41% F 62% D
Dividend Return 14.30% 85% B 66% D+
Total Return 5.26% 48% F 63% D
Average Annual (5 Year Horizon)  
Capital Gain 0.09% 28% F 36% F
Dividend Return 3.54% 42% F 40% F
Total Return 3.45% 87% B+ 73% C
Risk Return Profile  
Volatility (Standard Deviation) 14.96% 69% C- 86% B+
Risk Adjusted Return 23.65% 44% F 45% F
Market Capitalization 112.02B 86% B+ 100% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector